ATE222769T1 - Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens - Google Patents

Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens

Info

Publication number
ATE222769T1
ATE222769T1 AT97930090T AT97930090T ATE222769T1 AT E222769 T1 ATE222769 T1 AT E222769T1 AT 97930090 T AT97930090 T AT 97930090T AT 97930090 T AT97930090 T AT 97930090T AT E222769 T1 ATE222769 T1 AT E222769T1
Authority
AT
Austria
Prior art keywords
csf
administration
recurrence
prevent
brain tumors
Prior art date
Application number
AT97930090T
Other languages
English (en)
Inventor
Walter C Low
Margaret A Wallenfriedman
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of ATE222769T1 publication Critical patent/ATE222769T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97930090T 1996-06-27 1997-06-18 Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens ATE222769T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/671,251 US5837231A (en) 1996-06-27 1996-06-27 GM-CSF administration for the treatment and prevention of recurrence of brain tumors
PCT/US1997/010540 WO1997049421A1 (en) 1996-06-27 1997-06-18 Gm-csf administration for the treatment and prevention of recurrence of brain tumors

Publications (1)

Publication Number Publication Date
ATE222769T1 true ATE222769T1 (de) 2002-09-15

Family

ID=24693739

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97930090T ATE222769T1 (de) 1996-06-27 1997-06-18 Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens

Country Status (9)

Country Link
US (1) US5837231A (de)
EP (1) EP0912192B1 (de)
JP (1) JP2000515127A (de)
AT (1) ATE222769T1 (de)
AU (1) AU3400297A (de)
CA (1) CA2258608A1 (de)
DE (1) DE69715000T2 (de)
DK (1) DK0912192T3 (de)
WO (1) WO1997049421A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6395876B1 (en) 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
AU765529B2 (en) * 1998-05-26 2003-09-18 Genitrix, Llc Compositions and methods of modulating an immune response to an antigen
AU5458500A (en) * 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
CA2422454A1 (en) * 2000-09-15 2002-03-21 Ortho-Mcneil Pharmaceutical, Inc. Compositions and methods for inducing specific cytolytic t cell responses
CA2441434A1 (en) * 2001-03-12 2002-09-19 Institute Of Gene And Brain Science Remedies for nerve damages
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US20050186289A1 (en) * 2003-04-01 2005-08-25 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US20060234941A1 (en) * 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
US8142781B2 (en) * 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2007081878A2 (en) * 2006-01-07 2007-07-19 Medical College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
US8497246B2 (en) * 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
JP5901877B2 (ja) 2007-07-27 2016-04-13 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． 中枢神経系のα−Ｌ−イデュロニダーゼ活性を増加させるための方法および組成物
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
ES2725200T3 (es) 2009-10-09 2019-09-20 Armagen Inc Métodos y composiciones para aumentar la actividad de iduronato 2-sulfatasa en el SNC
KR20140103122A (ko) * 2011-11-17 2014-08-25 넨키 인스티튜트 오브 익스페리멘탈 바이올로지 신경교종을 치료하기 위한 조성물 및 방법
US20150024008A1 (en) * 2011-11-21 2015-01-22 The University Of Chicago Methods and Compositions Involving Induced Senescent Cells for Cancer Treatment
EP4338797A3 (de) 2011-12-02 2024-06-12 Armagen, Inc. Verfahren und zusammensetzungen zur erhöhung der arylsulfatase-a-aktivität im zns
SMT202100545T1 (it) 2012-05-16 2021-11-12 Stemline Therapeutics Inc Vaccini contro il cancro mirati alle cellule staminali cancerose
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5208022A (en) * 1988-05-19 1993-05-04 State University Of New York (Suny) Non-malignant cells coupled to adjuvants and their use in a method to induce anti-tumor immunity
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
EP1216710B1 (de) * 1991-10-04 2006-04-05 Whitehead Institute For Biomedical Research Regulierung der systemischen Immunantworten mittels Zytokinen und Antigenen

Also Published As

Publication number Publication date
JP2000515127A (ja) 2000-11-14
EP0912192A1 (de) 1999-05-06
DE69715000T2 (de) 2003-01-02
EP0912192B1 (de) 2002-08-28
WO1997049421A1 (en) 1997-12-31
US5837231A (en) 1998-11-17
DK0912192T3 (da) 2002-12-02
CA2258608A1 (en) 1997-12-31
AU3400297A (en) 1998-01-14
DE69715000D1 (de) 2002-10-02

Similar Documents

Publication Publication Date Title
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
DK0585943T3 (da) Opløselige ligander for CD40
DE60032795D1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE69703649D1 (de) Behandlung von deagglomerierten teilchen mit plasmaaktivierter spezies
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
EP1080113A4 (de) Behandlung von humanen tumoren mit bestrahlung und inhibitoren der wachstumsfaktorrezeptor-tyrosinkinase
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
EP0161606A3 (en) Drug, and methods of preparing and using it for treatment of tumors
DE3888378D1 (de) Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
BR9607894A (pt) Processo para tratar tumores
DE69519937D1 (de) Polyamin-verbindungen zur behandlung von proliferativer erkrankungen
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
DE69729004D1 (de) Photodynamische therapie zur behandlung von osteosrthritis
PT971710E (pt) Utilizacao de queleritrina e radiacao para terapia de tumores
ATE77961T1 (de) Verfahren zur behandlung der unfruchtbarkeit und mittel zur verwendung dabei.
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE58904722D1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE237697T1 (de) Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit
MY105075A (en) Cancer treatment
AU1502388A (en) Use of odc inhibitors, dacarbazine, and interferon in the treatment of malignant melanoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties